Novel Therapies for FSGS: Preclinical and Clinical Studies

Advances in Chronic Kidney Disease

Volumn 22, Issue 2, 2015, Pages e1-e6

  Malaga Dieguez, Laura ^a,b   Bouhassira, Diana ^a,b   Gipson, Debbie ^a,b   Trachtman, Howard ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Circulating factors; Fibrosis; FSGS; Immune modulators; Inflammation

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABATACEPT; ADALIMUMAB; ANTIFIBROTIC AGENT; CORTICOTROPIN; DECORIN; FRESOLIMUMAB; GALACTOSE; MELANOCORTIN 1 RECEPTOR; MICRORNA; PACLITAXEL; PIRFENIDONE; RESVERATROL; RITUXIMAB; ROSIGLITAZONE; SOLUBLE UROKINASE RECEPTOR; SPHINGOMYELIN PHOSPHODIESTERASE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; MONOCLONAL ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STABILITY; ENZYME BINDING; ENZYME REGULATION; EXTRACELLULAR MATRIX; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOMODULATION; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIPID METABOLISM; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PLASMAPHERESIS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; ADULT; CHILD; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; EXPERIMENTAL THERAPY; FIBROSIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; KIDNEY FAILURE, CHRONIC; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; DISEASE PROGRESSION; FIBROSIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOMODULATION; KIDNEY FAILURE, CHRONIC; PODOCYTES; THERAPIES, INVESTIGATIONAL;

EID: 84923846187     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.10.001     Document Type: Review

References (61)

1. D'Agati V.D., Kaskel F.J., Falk R.J. Focal segmental glomerulosclerosis. N Engl J Med 2011, 365(25):2398-2411.
2. D'Agati V.D., Alster J.M., Jennette J.C., et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 2013, 8(3):399-406.
3. Schell C., Huber T.B. New players in the pathogenesis of focal segmental glomerulosclerosis. Nephrol Dial Transplant 2012, 27(9):3406-3412.
4. Kitiyakara C., Kopp J.B., Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol 2003, 23(2):172-182.
5. Gipson D.S., Trachtman H., Kaskel F.J., et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011, 80(8):868-878.
6. Sethna C.B., Gipson D.S. The treatment of FSGS in children. Adv Chr Kid Dis 2014, 21:194-199.
7. Fogo A.B. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 2003, 23(2):161-171.
8. de Mik S.M., Hoogduijn M.J., de Bruin R.W., Dor F.J. Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models. BMC Nephrol 2013, 14:74.
9. Pescovitz M.D., Book B.K., Sidner R.A. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006, 354(18):1961-1963.
10. Fernandez-Fresnedo G., Segarra A., González E., et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009, 4(8):1317-1323.
11. Fornoni A., Sageshima J., Wei C., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011, 3(85):85ra46.
12. Rapoport M., McCrory C.W., Barbero G., Barnett H.L., Forman C.W. Effect of corticotropin (ACTH) on children with the nephrotic syndrome. J Am Med Assoc 1951, 147(12):1101-1106.
13. Barnett H.L. Effect of ACTH in children with the nephrotic syndrome. Pediatrics 1952, 9(3):341.
14. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2012, 8(2):122-128.
15. Hogan J., Bomback A.S., Mehta K., et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone Gel. Clin J Am Soc Nephrol 2013, 8(12):2072-2081.
16. Lindskog A., Ebefors K., Johansson M.E., et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010, 21(8):1290-1298.
17. Reiser J., von Gersdorff G., Loos M., et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004, 113(10):1390-1397.
18. Yu C.C., Fornoni A., Weins A., et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013, 369(25):2416-2423.
19. Joy M.S., Gipson D.S., Powell L., et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 2010, 55(1):50-60.
20. Peyser A., Machardy N., Tarapore F., et al. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol 2010, 11:2.
21. McCarthy E.T., Sharma M., Savin V.J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5(11):2115-2121.
22. Savin V.J., McCarthy E.T., Sharma R., Charba D., Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 2008, 151(6):288-292.
23. De Smet E., Rioux J.P., Ammann H., Deziel C., Querin S. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 2009, 24(9):2938-2940.
24. Jhaveri K.D., Naber T.H., Wang X., et al. Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation. Transplantation 2011, 91(6):e35-e36.
25. Kopac M., Meglic A., Rus R.R. Partial remission of resistant nephrotic syndrome after oral galactose therapy. Ther Apher Dial 2011, 15(3):269-272.
26. Savin V.J., McCarthy E.T., Sharma R., Reddy S., Dong J., Hess S., Kopp J. Cardiotrophin-like cytokine-1: candidate for the focal glomerulosclerosis permeability factor. J Am Soc Nephrol 2008, 19.
27. Wei C., El Hindi S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17(8):952-960.
28. Wei C., Trachtman H., Li J., et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012, 23(12):2051-2059.
29. Alachkar N., Wei C., Arend L.J., et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 2013, 96(7):649-656.
30. Bock M.E., Price H.E., Gallon L., Langman C.B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 2013, 8(8):1304-1311.
31. Meijers B., Maas R.J., Sprangers B., et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 2014, 85(3):636-640.
32. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006, 69(2):213-217.
33. Ashraf S., Gee H.Y., Woerner S., et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 2013, 123(12):5179-5189.
34. Kim J.H., Kim B.K., Moon K.C., Hong H.K., Lee H.S. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003, 64(5):1715-1721.
35. Strehlau J., Schachter A.D., Pavlakis M., Singh A., Tejani A., Strom T.B. Activated intrarenal transcription of CTL-effectors and TGF-beta1 in children with focal segmental glomerulosclerosis. Kidney Int 2002, 61(1):90-95.
36. Li J., Campanale N.V., Liang R.J., Deane J.A., Bertram J.F., Ricardo S.D. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006, 169(5):1527-1540.
37. Wan Y.G., Che X.Y., Sun W., et al. Low-dose of multi-glycoside of Tripterygium wilfordii Hook. f., a natural regulator of TGF-beta1/Smad signaling activity improves adriamycin-induced glomerulosclerosis invivo. J Ethnopharmacol 2014, 151(3):1079-1089.
38. Huang X., Wen D., Zhang M., et al. Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-beta/Smad3 pathway. J Cell Biochem 2013, 115(5):996-1005.
39. Kelly D.J., Zhang Y., Gow R., Gilbert R.E. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004, 15(10):2619-2629.
40. Border W.A., Noble N.A., Yamamoto T., et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992, 360(6402):361-364.
41. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45(4):522-530.
42. Ziyadeh F.N., Hoffman B.B., Han D.C., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97(14):8015-8020.
43. Trachtman H., Fervenza F.C., Gipson D.S., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011, 79(11):1236-1243.
44. Cho M.E., Smith D.C., Branton M.H., Penzak S.R., Kopp J.B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2(5):906-913.
45. Kasinath B.S., Feliers D. The complex world of kidney microRNAs. Kidney Int 2011, 80(4):334-337.
46. Chandrasekaran K., Karolina D.S., Sepramaniam S., et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int 2012, 81(7):617-627.
47. Lorenzen J.M., Haller H., Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 2011, 7(5):286-294.
48. Zarjou A., Yang S., Abraham E., Agarwal A., Liu G. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 2011, 301(4):F793-F801.
49. Denby L., Ramdas V., Lu R., et al. MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol 2014, 25(1):65-80.
50. Li R., Chung A.C., Dong Y., Yang W., Zhong X., Lan H.Y. The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-beta/Smad3-Azin1 pathway. Kidney Int 2013, 84(6):1129-1144.
51. Sun L., Zhang D., Liu F., et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol 2011, 225(3):364-377.
52. Wu J., Zheng C., Fan Y., et al. Downregulation of MicroRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. J Am Soc Nephrol 2014, 25(1):92-104.
53. Zhang D., Sun L., Xian W., et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest 2010, 90(3):436-447.
54. Kincaid-Smith P., Fairley K.F., Farish S., Best J.D., Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008, 13(1):58-62.
55. Joy M.S., Gipson D.S., Dike M., et al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol 2009, 4(1):39-47.
56. Kunter U., Rong S., Djuric Z., et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006, 17(8):2202-2212.
57. Morigi M., Imberti B., Zoja C., et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004, 15(7):1794-1804.
58. Ma H., Wu Y., Xu Y., Sun L., Zhang X. Human umbilical mesenchymal stem cells attenuate the progression of focal segmental glomerulosclerosis. Am J Med Sci 2013, 346(6):486-493.
59. Ruan G.P., Xu F., Li Z.A., et al. Induced autologous stem cell transplantation for treatment of rabbit renal interstitial fibrosis. PLoS One 2013, 8(12):e83507.
60. Belingheri M., Lazzari L., Parazzi V., et al. Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis. Biologicals 2013, 41(6):439-445.
61. Gadegbeku C.A., Gipson D.S., Holzman L.B., et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013, 83(4):749-756.